OLR1 and myeloid sarcoma: Examination of paired blood samples from MS patients during relapse and at a follow-up visit revealed an increase in the frequency of LOX1+ PMN-MDSCs in those who achieved complete control of inflammatory disease activity and met the criteria for “no evidence of disease activity”, whereas no significant changes were observed in those with ongoing disease activity [42].